Impact of Human Epidermal Growth Factor Receptor 2 (HER2) Low Status in Response to Neoadjuvant Chemotherapy in Early Breast Cancer

Introduction In clinical practice, there is a binary distinction between human epidermal growth factor receptor 2 (HER2)-positive and HER2-negative (HER2−) breast cancer (BC). However, within HER2− disease, there is significant heterogeneity. Particularly, HER2− tumors that express some level of HER...

Descripción completa

Detalles Bibliográficos
Autores principales: Alves, Fátima R, Gil, Lucia, Vasconcelos de Matos, Leonor, Baleiras, Ana, Vasques, Carolina, Neves, Maria Teresa, Ferreira, André, Fontes-Sousa, Mário, Miranda, Helena, Martins, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Pathology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938239/
https://www.ncbi.nlm.nih.gov/pubmed/35371692
http://dx.doi.org/10.7759/cureus.22330

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8938239/
https://www.ncbi.nlm.nih.gov/pubmed/35371692
http://dx.doi.org/10.7759/cureus.22330

Ejemplares similares